BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 2274397)

  • 1. [Immunotherapy of malignant melanoma].
    Flageul B; Miclea JM; Bensussan A; Degos L
    Pathol Biol (Paris); 1990 Oct; 38(8):881-2. PubMed ID: 2274397
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunotherapy of malignant melanoma.
    Oratz R; Bystryn JC
    Dermatol Clin; 1991 Oct; 9(4):669-82. PubMed ID: 1718648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapy with interleukin-2 and tumor-derived activated lymphocytes.
    Oldham RK
    Immunol Ser; 1994; 61():251-71. PubMed ID: 8011748
    [No Abstract]   [Full Text] [Related]  

  • 4. [Treatment of metastatic melanoma with interleukin-2].
    Chosidow O; Guillaume JC
    Ann Dermatol Venereol; 1992; 119(1):65-73. PubMed ID: 1373275
    [No Abstract]   [Full Text] [Related]  

  • 5. [Interleukin-2 and adoptive immunotherapy: their biological aspects and clinical application in oncology].
    Barón Saura JM; Pizarro Redondo A; Berrocal Jaime A; González Barón M
    Rev Clin Esp; 1991 May; 188(9):468-72. PubMed ID: 1896596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor-derived activated cells: culture conditions and characterization.
    Maleckar JR; Friddell CS; Lewko WM; Yannelli JR; West WH; Oldham RK
    Immunol Ser; 1989; 48():159-73. PubMed ID: 2488319
    [No Abstract]   [Full Text] [Related]  

  • 7. [A new therapeutic concept in the treatment of metastatic cancers of the kidney: the TIL (tumor infiltrating lymphocytes)].
    Peyret C
    J Urol (Paris); 1991; 97(2):63-71. PubMed ID: 2071925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New perspectives in immunotherapy of leukemia.
    Lotzová E
    Immunol Ser; 1994; 61():231-8. PubMed ID: 8011747
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment of malignant melanoma with interleukin-2.
    Philip PA; Flaherty L
    Semin Oncol; 1997 Feb; 24(1 Suppl 4):S32-8. PubMed ID: 9122732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T-cell receptor beta variable region diversity in melanoma metastases after interleukin 2-based immunotherapy.
    Willhauck M; Möhler T; Scheibenbogen C; Pawlita M; Brossart P; Schmier JW; Keilholz U
    Clin Cancer Res; 1996 Apr; 2(4):767-72. PubMed ID: 9816229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adoptive immunotherapy.
    Sznol M; Urba WJ
    Cancer Chemother Biol Response Modif; 1994; 15():213-25. PubMed ID: 7779587
    [No Abstract]   [Full Text] [Related]  

  • 12. Studies of the immunological effects of interleukin-2 in patients with bladder cancer and renal cell carcinoma.
    Hermann GG
    APMIS Suppl; 1993; 35():1-26. PubMed ID: 8251200
    [No Abstract]   [Full Text] [Related]  

  • 13. [Adoptive immunotherapy in patients with multiple hepatic cancers using lymphokine activated killer cells (LAK) and interleukin-2].
    Kanai T; Monden M; Takeda T; Gotoh M; Sakon M; Umeshita K; Hasuike Y; Sakita I; Nakano H; Yoshida T
    Gan To Kagaku Ryoho; 1993 Aug; 20(11):1457-60. PubMed ID: 8396896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
    Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
    In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adoptive cellular immunotherapy of cancer: future perspectives.
    Stevenson HC
    Immunol Ser; 1989; 48():229-36. PubMed ID: 2488324
    [No Abstract]   [Full Text] [Related]  

  • 16. Lymphokine-activated killer lymphocytes: LAK and interleukin-2 in the treatment of malignancies of the central nervous system.
    Blacklock JB; Grimm EA
    Immunol Ser; 1989; 48():93-9. PubMed ID: 2488328
    [No Abstract]   [Full Text] [Related]  

  • 17. Autologous activated lymphocyte therapy in a community hospital.
    Horváth J; Szabó-Szabari M; Sinkovics JG
    Acta Microbiol Immunol Hung; 1994; 41(2):205-14. PubMed ID: 7804724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A study of the cytotoxicity of malignant pleural effusion lymphocytes and LAK cells against autologous tumor cells.
    Guo YS; Xing ZL
    Chin Med J (Engl); 1994 Dec; 107(12):903-5. PubMed ID: 7882727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adoptive cellular therapy.
    Sznol M; Urba WJ
    Cancer Chemother Biol Response Modif; 1992; 13():191-204. PubMed ID: 1389910
    [No Abstract]   [Full Text] [Related]  

  • 20. Cellular immunotherapy of cancer.
    Yang JC
    Curr Opin Gen Surg; 1994; ():238-44. PubMed ID: 7583979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.